Chief Financial Officer
Eric d’Esparbes joined the company as Chief Financial Officer in 2019, leading the finance, accounting, revenue cycle management, and investor relations teams. With a focus on establishing strong financial controls and resolving legacy company challenges, he led the effort to bring the company public in 2020, raising capital to support the company’s key innovation programs. He was also one of the leading forces behind its transformation into a highly focused biotherapeutics company.
Mr. d’Esparbes brings more than 27 years of financial and executive experience in strategic planning and fund-raising functions for both private and public companies. Previously, he was the CFO and interim Principal Executive Officer of Innoviva, Inc. (NASDAQ:INVA), a publicly traded biotechnology company managing a portfolio of drug-device combination medicines for the treatment of asthma and chronic obstructive pulmonary disease, which are sold globally by GlaxoSmithKline. During his time at Innoviva, Mr. d’Esparbes led the optimization of the company’s capital structure and helped develop and implement a strategic plan to transition the company to a higher margin business.
Prior to this, he held leadership positions as CFO for Joule Unlimited, Vice President of Finance for global energy company AEI, Inc., and CFO for Meiya Power Company (now CNG New Energy), where he collaborated with large private equity investors to raise and optimize capital. In his previous roles, he was responsible for profit and loss management of up to $3.5 billion annual global sales. Mr. d’Esparbes holds a bachelor’s degree from Hautes Études Commercial in Montréal, Canada.